Detailed Atomistic Analysis of the HIV-1 Protease Interface

被引:14
|
作者
Sousa, Sergio Filipe [1 ]
Tamames, Bruno [1 ]
Fernandes, Pedro Alexandrino [1 ]
Ramos, Maria Joao [1 ]
机构
[1] Univ Porto, Fac Ciencias, Dept Quim & Bioquim, REQUIMTE, P-4169007 Oporto, Portugal
来源
JOURNAL OF PHYSICAL CHEMISTRY B | 2011年 / 115卷 / 21期
关键词
ALANINE-SCANNING MUTAGENESIS; SMALL-MOLECULE INHIBITORS; HUMAN-IMMUNODEFICIENCY; HOT-SPOT; BINDING-ENERGY; CRYSTAL-STRUCTURES; DRUG-RESISTANCE; COMPLEX; DYNAMICS; DIMERIZATION;
D O I
10.1021/jp200075s
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
HIV-1 protease is a very attractive target for the development of new anti-HIV drugs and has been extensively studied over the past decades. In this study, we present a detailed atomic level characterization of the dimer interface in the enzyme HIV-1 protease through computational alanine scanning mutagenesis and molecular dynamics simulations. In addition to a full mapping of the amino acid residues present at the subunit interface, in terms of the corresponding energetic contribution for dimer formation and of their dassification as hot spots, warm spots, and null spots, we trace a dynamic analysis of the subunit interacting and solvent accessible surface areas and of the most important hydrogen bonds between subunits. The results presented illustrate the high energetic importance for dimer formation of a small set of five amino acid residue pairs at the subunit interface-LeuS, Ile50, Arg87, Leu97, and Phe99-and provide important dues on the most important structural and energetic determinants for dimer formation. In addition, the results presented suggest several key targets at the subunit interface for the development of new molecules that aim to inhibit HIV-1 protease (PR) activity through blocking the formation of the fully active PR homodimeric form, providing important clues for drug design.
引用
收藏
页码:7045 / 7057
页数:13
相关论文
共 50 条
  • [1] Atomistic simulations of the HIV-1 protease folding inhibition
    Verkhivker, Gennady
    Tiana, Guido
    Camilloni, Carlo
    Provasi, Davide
    Broglia, Ricardo A.
    [J]. BIOPHYSICAL JOURNAL, 2008, 95 (02) : 550 - 562
  • [2] HIV-1 Protease: a computational mutagenesis analysis of the monomers interface
    Tamames, B.
    Fernandes, P. Alexandrino
    Ramos, M. J.
    [J]. FEBS JOURNAL, 2009, 276 : 167 - 167
  • [3] THE INHIBITION OF HIV-1 PROTEASE BY INTERFACE PEPTIDES
    SCHRAMM, HJ
    BILLICH, A
    JAEGER, E
    RUCKNAGEL, KP
    ARNOLD, G
    SCHRAMM, W
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1993, 194 (02) : 595 - 600
  • [4] Rigidity analysis of HIV-1 protease
    Heal, J. W.
    Wells, S. A.
    Jimenez-Roldan, E.
    Freedman, R. F.
    Roemer, R. A.
    [J]. CONDENSED MATTER AND MATERIALS PHYSICS CONFERENCE (CMMP10), 2011, 286
  • [5] Interface targeting peptides as inhibitors of HIV-1 protease mutants
    Schramm, Hans J.
    Schramm, Wolfgang
    [J]. ACTA PHARMACOLOGICA SINICA, 2006, 27 : 51 - 51
  • [6] Targeting the dimerization interface for irreversible inhibition of HIV-1 protease
    Zutshi, R
    Chmielewski, J
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (17) : 1901 - 1903
  • [7] Conformational analysis of HIV-1 protease inhibitors
    Brown, Jeanice
    Parish, Carol A.
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 : 52 - 52
  • [8] Binding pathways of ligands to HIV-1 protease: Coarse-grained and atomistic simulations
    Chang, Chia-En A.
    Trylska, Joanna
    Tozzini, Valentina
    McCammon, J. Andrew
    [J]. CHEMICAL BIOLOGY & DRUG DESIGN, 2007, 69 (01) : 5 - 13
  • [9] Inhibitor binding at the protein interface in crystals of a HIV-1 protease complex
    Brynda, J
    Rezácová, P
    Fábry, M
    Horejsí, M
    Stouracová, R
    Soucek, M
    Hradílek, M
    Konvalinka, J
    Sedlácek, J
    [J]. ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2004, 60 : 1943 - 1948
  • [10] HIV-1 protease inhibitors: A comparative QSAR analysis
    Kurup, A
    Mekapati, SB
    Garg, R
    Hansch, C
    [J]. CURRENT MEDICINAL CHEMISTRY, 2003, 10 (17) : 1679 - 1688